相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Mammalian Target of Rapamycin: Its Role in Early Neural Development and in Adult and Aged Brain Function
Carla Garza-Lombo et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2016)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
Daily Oral Everolimus Activity in Patients With Metastatic Pancreatic Neuroendocrine Tumors After Failure of Cytotoxic Chemotherapy: A Phase II Trial
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402
Christoph M. Dehnhardt et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Dependence on Phosphoinositide 3-Kinase and RAS-RAF Pathways Drive the Activity of RAF265, a Novel RAF/VEGFR2 Inhibitor, and RAD001 (Everolimus) in Combination
Pierre Mordant et al.
MOLECULAR CANCER THERAPEUTICS (2010)
AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines
Dana S. Levy et al.
BLOOD (2009)
Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2
Mamta Gupta et al.
BLOOD (2009)
Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts
P. Cao et al.
BRITISH JOURNAL OF CANCER (2009)
A Phase 2 Study With a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients With Metastatic Clear Cell Renal Cell Cancer
Robert J. Amato et al.
CANCER (2009)
PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells
Fengxue Zhang et al.
CANCER BIOLOGY & THERAPY (2009)
mTOR Complex 2 Is Required for the Development of Prostate Cancer Induced by Pten Loss in Mice
David A. Guertin et al.
CANCER CELL (2009)
Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy
Lei Fu et al.
CANCER RESEARCH (2009)
Signaling Events Downstream of Mammalian Target of Rapamycin Complex 2 Are Attenuated in Cells and Tumors Deficient for the Tuberous Sclerosis Complex Tumor Suppressors
Jingxiang Huang et al.
CANCER RESEARCH (2009)
The role of mTOR in the management of solid tumors: An overview
Alex S. Strimpakos et al.
CANCER TREATMENT REVIEWS (2009)
Randomized Phase II Study Comparing Two Schedules of Everolimus in Patients With Recurrent/Metastatic Breast Cancer: NCIC Clinical Trials Group IND.163
Susan L. Ellard et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Georg Hess et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas
Ta-Jen Liu et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
Florence I. Raynaud et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
Saskia M. Brachmann et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Perifosine: Update on a Novel Akt Inhibitor
Joell J. Gills et al.
CURRENT ONCOLOGY REPORTS (2009)
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Morris E. Feldman et al.
PLOS BIOLOGY (2009)
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Jeffrey A. Engelman
NATURE REVIEWS CANCER (2009)
A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
Neil E. Torbett et al.
BIOCHEMICAL JOURNAL (2008)
TOR complex 2 is needed for cell cycle progression and anchorage-independent growth of MCF7 and PC3 tumor cells
Ville Hietakangas et al.
BMC CANCER (2008)
MTORCI inhibitors: is temsirolimus in renal cancer telling us how they really work?
C. Le Tourneau et al.
BRITISH JOURNAL OF CANCER (2008)
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity
Joseph R. Garlich et al.
CANCER RESEARCH (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity
Nelson Rhodes et al.
CANCER RESEARCH (2008)
Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation
Xuerong Wang et al.
CANCER RESEARCH (2008)
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies
David A. Rizzieri et al.
CLINICAL CANCER RESEARCH (2008)
Mechanism of action of rapalogues: the antiangiogenic hypothesis
Sandrine Faivre et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2008)
Identification of 4-(2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3S)-3-piperidinylmethyl]oxy}-1H-imidazo[4,5-c]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a novel inhibitor of AKT kinase
Dirk A. Heerding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer
Adrian J. Folkes et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
The TSC1-TSC2 complex is required for proper activation of mTOR complex 2
Jingxiang Huang et al.
MOLECULAR AND CELLULAR BIOLOGY (2008)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia
Federica Fala et al.
MOLECULAR PHARMACOLOGY (2008)
The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism
F. Chiarini et al.
LEUKEMIA (2008)
Regulation of TORC1 by Rag GTPases in nutrient response
Eunjung Kim et al.
NATURE CELL BIOLOGY (2008)
mTORC2 activity is elevated in gliomas and promotes growth and cell motility via overexpression of rictor
Janine Masri et al.
CANCER RESEARCH (2007)
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial
Karen G. Chee et al.
CLINICAL GENITOURINARY CANCER (2007)
Akt inhibitor A-443654 induces rapid Akt Ser-473 phosphorylation independent of mTORC1 inhibition
E. K-H Han et al.
ONCOGENE (2007)
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway
Heath A. Elrod et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML
Zhihong Zeng et al.
BLOOD (2007)
The tuberous sclerosis complex
Peter B. Crino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Current development of mTOR inhibitors as anticancer agents
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
New paradigms in anticancer therapy: Targeting multiple signaling pathways with kinase inhibitors
Sandrine Faivre et al.
SEMINARS IN ONCOLOGY (2006)
Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells
Teru Hideshima et al.
BLOOD (2006)
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB
DD Sarbassov et al.
MOLECULAR CELL (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations
ND Rendtorff et al.
HUMAN MUTATION (2005)
Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition
SY Sun et al.
CANCER RESEARCH (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma
TE Witzig et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo
Y Luo et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Dysregulation of the TSC-mTOR pathway in human disease
K Inoki et al.
NATURE GENETICS (2005)
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
MB Atkins et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton
DD Sarbassov et al.
CURRENT BIOLOGY (2004)
Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling
K Inoki et al.
GENES & DEVELOPMENT (2003)
Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins
Y Zhang et al.
NATURE CELL BIOLOGY (2003)